On 29 May 2026, the European Medicines Agency (EMA) published a concept paper outlining the need to revise its guideline on the development of medicinal products for the treatment of smoking. The document, issued by EMA's Committee for Medicinal Products for Human Use (CHMP), signals a potential update to regulatory requirements for smoking cessation therapies, impacting pharmaceutical developers and public health stakeholders.
The concept paper identifies gaps in the current guideline, which dates from 2008, particularly regarding novel product types such as nicotine-containing electronic cigarettes and combination therapies. EMA proposes to align the revised guideline with evolving scientific evidence on smoking cessation, including behavioural support integration and long-term efficacy endpoints. The paper invites stakeholders to submit comments by 30 September 2026, after which EMA will draft a revised guideline.
Policy orientations and trade-offs EMA's revision aims to improve the quality and consistency of clinical trials for smoking cessation products, potentially accelerating patient access to effective treatments. However, stricter efficacy and safety requirements could increase development costs for manufacturers, particularly small and medium-sized enterprises. The concept paper also raises questions about the regulatory status of e-cigarettes as medicinal products versus consumer goods, a long-standing debate in EU health policy.
Impact on stakeholders Pharmaceutical companies developing smoking cessation therapies face potential changes in trial design, endpoint selection, and post-marketing surveillance obligations. Public health authorities may benefit from clearer evidence standards to support reimbursement decisions. Healthcare professionals could gain access to better-validated treatment options. Patients may see improved efficacy and safety profiles, though delays in market entry could limit immediate availability.
Expected institutional follow-up Following the public consultation, EMA's CHMP will prepare a draft revised guideline, expected in 2027. The final guideline will replace the 2008 version and will be implemented across EU member states. The revision aligns with the EU's Beating Cancer Plan and the Tobacco Products Directive, which aim to reduce smoking prevalence to below 5% by 2040.
← Atlas › News › Health & Lifestyle